Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly To Give High-Risk Alzheimer’s Drug “Every Chance,” says Lechleiter At JP Morgan

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly is relying heavily on biomarkers to help its Alzheimer’s disease-modifying drug solanezumab progress, executives tell a crowd of analysts at JP Morgan,


Related Content

Alzheimer’s Research To Be More Collaborative, Better Funded Under National Plan
First Quarter Updates, In Brief
Pharma At Barclays, In Brief
Business News, In Brief
Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial
Bristol Opens A Phase III Door Into Gamma Secretase As Lilly Closes Another


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts